#USA #New York #Levi & Korsinsky #Securities Fraud #Neumora Therapeutics

Neumora Therapeutics, Inc. Shareholders Urged to Act

Neumora Therapeutics, Inc., a company traded on NASDAQ under the symbol NMRA, finds itself embroiled in a significant securities fraud class action lawsuit. Shareholders are being urged to contact Levi & Korsinsky, LLP to discuss their rights and potential compensations before the upcoming deadline of April 7, 2025.

The lawsuit aims to address alleged securities fraud that adversely affected investors during a crucial offering period that started approximately on September 15, 2023. The main claims revolve around misleading information related to Neumora's clinical trials, specifically concerning its treatment for Major Depressive Disorder (MDD). Allegations suggest that the defendants made false statements and concealed critical details which could mislead potential investors and harm their financial interests.

Class Action Details

The class action lawsuit seeks to recover losses for all individuals or entities that purchased Neumora's common stock tied to the offering documents during the designated timeframe. This collective action is designed to protect the rights of investors who have suffered losses as a result of the alleged fraudulent activities by the company.

The filed complaint against Neumora alleges that:
1. Altered Inclusion Criteria: Neumora was compelled to amend its Phase Two trial's inclusion criteria for MDD patients, a move intended to show a statistically significant improvement with its flagship candidate, Navacaprant.
2. Inadequate Data: The Phase Two trial reportedly lacked adequate data concerning the patient population size and the gender ratio within that population—factors critical for accurate prediction of trial outcomes.
3. New Analytical Focus: A new prespecified analysis was added to the Phase Two statistical analysis plan, which focused on patients suffering from moderate to severe MDD. These adjustments may not have been sufficiently communicated to investors, raising serious questions about transparency.

Next Steps for Affected Shareholders

For those who believe they may be impacted by this matter, it is crucial to take action quickly. Investors can request to be appointed as lead plaintiffs in the class action lawsuit up until the April 7, 2025 deadline. However, participating in the lawsuit as a class member does not require leading the action; recovery options are available to all eligible shareholders.

No Upfront Costs for Participating Shareholders

Levi & Korsinsky ensures that class members do not need to worry about out-of-pocket expenses, as participation is without any financial obligation. The firm has established a strong track record over two decades of representing investors in complex securities litigation, winning hundreds of millions of dollars for aggrieved shareholders. They have been recognized consistently among the top securities litigation firms in the United States, with specialized expertise in handling investor rights cases.

Contact Information

For further inquiry or to participate, shareholders are encouraged to reach out directly to Joseph E. Levi, Esq., or Ed Korsinsky, Esq. at Levi & Korsinsky, LLP. They can be contacted via email at info@zlk.com or by phone at (212) 363-7500.

With the looming deadline, it is vital for shareholders of Neumora Therapeutics to realize their rights and the potential compensation avenues available. Shareholders are strongly encouraged to act now to ensure they are represented and their interests safeguarded through this potential recovery avenue.